Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis (Q33226226)

24 July 2017

0 references

1 reference

title

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis (English)

1 reference

24 July 2017

0 references

Lars Hjalmar Lindholm

series ordinal

1

1 reference

24 July 2017

Bo Carlberg

series ordinal

2

1 reference

24 July 2017

Ola Samuelsson

series ordinal

3

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

24 July 2017

1 reference

24 July 2017

volume

366

1 reference

24 July 2017

issue

9496

1 reference

24 July 2017

page(s)

1545-1553

1 reference

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

beta Blockade after myocardial infarction: systematic review and meta regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Are β-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

β-blockers in hypertension—the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Atenolol in hypertension: is it a wise choice?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Randomised trial of treatment of hypertension in elderly patients in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Blood pressure, stroke, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Cardiovascular protection and blood pressure reduction: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Effect of different antihypertensive drug classes on central aortic pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Global burden of hypertension: analysis of worldwide data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967573-3

7 January 2021

10.1016/S0140-6736(05)67573-3

Identifiers

DOI

1 reference

24 July 2017

1 reference